Nurix Therapeutics presents fresh preclinical and early clinical results for NX-5948 in CSU

Nurix Therapeutics presents fresh preclinical and early clinical results for NX-5948 in CSU
Nurix shares new NX-5948 data

Nurix Therapeutics announced the presentation of new preclinical and Phase 1 translational data focused on its investigational therapy, bexobrutideg (NX-5948), for chronic spontaneous urticaria (CSU) at the 2026 Society for Investigative Dermatology (SID) Annual Meeting.

The presented data aim to demonstrate the potential of NX-5948 in addressing unmet needs for CSU patients, reflecting Nurix Therapeutics' ongoing commitment to advancing research in immunological disorders. More information about the presentation and data can be found on the company’s official resources.

Nurix Therapeutics previously announced plans to share updated Phase 1a b data for its BTK degrader NX-5948 in chronic lymphocytic leukemia at the EHA2026 in June 2026. The company has focused development of NX-5948 across multiple indications. Recent data presentations highlight Nurix's research activity in both immunological and hematological disorders.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.